8/6/2020 8:08:38 AM
Lipocine Q2 Net Loss $6.4 Mln Or $0.13/shr Vs. Net Loss $3.4 Mln Or $0.14/shr Last Year
7/31/2020 8:12:42 AM
Lipocine Says Shareholder Derivative Action Was Dismissed By Chancery Court Of Delaware
5/13/2020 8:09:30 AM
Lipocine : Treatment Potential Of LPCN 1144 Demonstrated In A Pre-Clinical NASH And Hepatic Fibrosis Model
5/7/2020 8:10:20 AM
Lipocine Q1 Net Loss $5.8 Mln Or $0.14/shr Vs. Net Loss $3.2 Mln Or $0.14/shr Last Year
5/5/2020 8:06:30 AM
Lipocine Says FDA Clears LPCN 1148 IND Application For Phase 2 Cirrhosis Trial
4/17/2020 8:08:00 AM
Lipocine Says FDA Denied Citizen Petition Filed By Clarus Therapeutics On October 2, 2019
3/26/2020 8:05:33 AM
Lipocine Reports Outcome Of Markman Hearing In Patent Infringement Suit Against Clarus